Description
Release form
Lyophilizate for preparation of solution for infusion
Packing
1 fl.
Pharmacological action
Cancidas has an antifungal effect.
Indications
Esophageal candidiasis, oropharyngeal candidiasis, aspergillosis.
Contraindications
Hypersensitivity to any of the components of Cancidas.
Caution: combination with cyclosporine in patients with moderate hepatic insufficiency (from 7 to 9 points on the Child-Pugh scale).
Use during pregnancy and lactation
There is no clinical experience with the use of Cancidas in pregnant and lactating women. In animals, caspofungin crosses the placental barrier. Caspofungin should not be prescribed to women during pregnancy, except in cases where the appointment of the drug is vital.
Since there is no data on the allocation of caspofungin with milk of a nursing woman, if necessary, the appointment of the drug during lactation should stop breastfeeding.
Dosage and administration of
I / v drip for at least 1 hour
Esophageal and oropharyngeal cadidosis: 50 mg once daily.
Aspergillosis: On the first day, a single loading daily dose of 70 mg is administered. In the following days, the daily dose is 50 mg 1 time per day, if necessary, the dose can be increased to 70 mg 1 time per day. The duration of treatment depends on the severity of the underlying disease, recovery after immunosuppression, and the patient’s clinical response.
Side effects
Frequent (more than 1/100): hyperthermia, headache, abdominal pain, chills, nausea, diarrhea, vomiting, increased activity of liver enzymes (ALT, ACT, alkaline phosphatase, direct and indirect bilirubin), hypercreatininemia, anemia, phlebitis / thrombophlebitis, skin rash, itching.
Allergic reactions (rash, facial swelling, itching, sensation of heat, bronchospasm), anaphylaxis (shortness of breath and increased rash that arose earlier with the use of the drug).
Changes in laboratory parameters: hypoalbuminemia, hypoproteinemia, hypokalemia, hyponatremia, hypocalcemia, decreased Hb, leukopenia, eosinophilia, thrombocytopenia, neutropenia, increased APTT, increased prothrombin time, proteinuria, erythrocytosis.
Drug Interactions
Do not mix with other solutions (including those containing dextrose). Compatible with 0.9% NaCl, Ringer’s lactate solution.
Efavirenz, nelfinavir, nevirapine, rifampicin, dexamethasone, phenytoin, or carbamazepine with simultaneous administration lead to a decrease in the concentration of caspofungin in the plasma.
Does not affect the pharmacokinetics of itraconazole, amphotericin B, rifampicin or the active metabolites of mycophenolate mofetil.
Reduces tacrolimus concentration.
Cyclosporine increases AUC by 35%.
Rifampin can both accelerate and slow down the excretion of caspofungin.
Overdose of
Symptoms: There were no clinically significant symptoms when used in the highest dose – 210 mg.
Treatment: hemodialysis is ineffective.
Storage Conditions
In a dark place at 2-8 ° C.
Terms of delivery from drugstores
Prescription
Form of Treatment
simply entails dlya infusing
